Abstract
(5 min), following which sections were incubated with probes decreased albuminuria and structural changes comin humidified (50% formamide) chambers for 14-16 h at pared with 'IGF-I-replete' control diabetic rats [12, 13] . 60°C . Sections were washed in 2×standard saline citrate Following the initial rise in kidney IGF-I levels in (2×SSC; 0.3 M NaCl, 0.33 M Na 3 C 6 H 5 O 7 .2H 2 O) containing diabetic rats, renal IGF-I levels normalize or decrease 50% formamide at 55°C for 1.5 h. Sections were then washed below control levels (reviewed in [6 ] ), indicating either and treated with 150 mg/ml RNAase A for 1 h at 37°C that the predominant role of the IGF system is in the followed by a wash in 2×SSC at 55°C for 45 min. After development of the early changes of diabetes or that final dehydration through graded ethanol, slides were airmore sustained changes in the other components of dried and autoradiographed with Kodak XAR ( Eastman the IGF system are responsible for continuing effects. Kodak, New York) film for 1-3 days at room temperature.
Some slides were dipped in photographic emulsion
The actions of IGFs are modulated by a family (Amersham, UK ), stored with desiccant at 4°C for [14] [15] [16] [17] [18] [19] [20] [21] of six structurally related IGF binding proteins days, developed in Kodak D19, fixed in Ilford Hypam, and (IGFBPs). Under different circumstances, IGFBPs stained with haematoxylin for evaluation.
may potentiate or inhibit IGF actions [14] . Renal expression of IGFBPs is altered in STZ-diabetes Quantitation of in-situ hybridization histochemistry [15] [16] [17] [18] [19] [20] . Major changes include increased IGFBP-1
[22] levels and decreased IGFBP-4 levels. The aim of this study was to investigate whether aminoguanidine, Autoradiographs were quantitated using the MCID (Imaging which inhibits the development of diabetic nephroResearch, Ontario, Canada) computerized image analysis pathy, also normalizes changes in expression of IGF-I system. Regions of interest were traced out, and optical and IGFBPs 1-6. densities within those regions were quantified and calibrated by reference to 14C-radioactive standards (Amersham, UK ) which were simultaneously exposed with slides to X-ray film.
Subjects and methods
Results were corrected for non-specific labelling by subtracting the signal obtained using sense probes from that Animals obtained using antisense probes.
Male Sprague-Dawley rats weighing 200-250 g were made Immunohistochemistry diabetic by intravenous injection of streptozotocin (55 mg/kg in citrate buffer, pH 4.5). Control rats were injected with Standard techniques were employed using rabbit anti-mouse citrate buffer alone. Control and diabetic rats were random-IGFBP-1 and rabbit anti-human IGF-I polyclonal antisera ized to receive either aminoguanidine (AG, 1 g/l in drinking (GroPep, Adelaide, Australia), both of which cross-react water for the entire 8 months of the study) or no treatment. with rat antigens, at dilutions of 15200 and 15100 respectDiabetic rats did not receive insulin therapy. Urine of diabetic ively. The Elite Vectastain ABC kit ( Vector Laboratories, rats was regularly tested for ketones ( Ketostix, Bayer, Burlingame, CA) and the peroxidase method of labelling Mulgrave, Australia) and these were not detected. After 8 were used according to the manufacturer's instructions. months, blood was taken from the tail vein for glucose Negative control slides were incubated with normal goat measurement and animals were killed by intravenous serum instead of primary antibody. Nembutal injection. Kidneys were removed, weighed, and fixed in 10% neutral buffered formalin. This protocol was approved by the Austin and Repatriation Medical Centre Statistics Animal Welfare Committee.
Quantitative in-situ hybridization histochemistry data were log-transformed to stabilize variance prior to analysis.
In-situ hybridization histochemistry
Results were analysed by analysis of variance followed by Fisher's protected least significant difference test for specific In-situ hybridization histochemistry was performed as previ-comparisons between groups. Results are expressed as ously described [21] . Briefly, 35S-labelled complementary mean±SE. Two-sided P values are shown. (antisense) or non-complementary (sense) RNA probes were synthesized for rat IGFBP-1-6 and IGF-I. The cDNAs for IGFBPs 1-6 were kindly provided by Dr S. Shimasaki Results ( Whittier Institute, La Jolla, CA), and for IGF-I by Dr C. T. Roberts Jr (NIH, Bethesda, MD). Probes were adjusted As expected, diabetic rats had higher plasma glucose to an average length of 150 bases by alkaline hydrolysis. The average specific activity of the RNA probes generated was levels and urinary volumes than control rats, but 3×109 c.p.m./mg RNA. aminoguanidine had no effect on severity of diabetes Kidney sections (4 mm) were digested with Pronase E as measured by either parameter ( Table 1) . Control (Sigma, 125 mg/ml ), washed in 0.1 M sodium phosphate and diabetic rats treated with aminoguanidine weighed buffer, pH 7.2, ultrapure water, dehydrated in 70% ethanol, less than vehicle-treated rats (P=0.003, Table 1 ). and air-dried. The 35S-labelled RNA probes (5×105 However, diabetes resulted in a similar degree of weight c.p.m./25 ml hybridization buffer) were added to a hybridiza-loss in vehicle-and aminoguanidine-treated rats tion buffer consisting of 300 mM NaCl, 10 mM Tris-HC1, (diabetes×treatment interaction, P=0.23). Absolute pH 7.5, 10 mM Na 2 HPO 4 , pH 6.8, 5 mM EDTA, pH 8.0, and relative kidney weights were significantly higher 1×Denhardt's solution, 50 mg/ml yeast RNA, 50% deionized in diabetic rats (P<0.0001, Table 1 ) and treatment formamide, and 10% (w/v) dextran sulphate. The hybridization buffer containing labelled probe was preheated to 80°C with aminoguanidine had no effect on either parameter. Aminoguanidine ameliorates diabetes-related changes in (results not shown), were decreased by 79% compared with untreated control rats (P<0.001, Figure 4 ). In renal IGF-I, IGFBP-1, and IGFBP-4 expression aminoguanidine-treated diabetic rats, levels of IGF-I As previously described [15] [16] [17] [18] [19] [20] , the major effects of mRNA were decreased by only 39% compared with diabetes on gene expression of IGF system components aminoguanidine-treated controls, a difference that did were increased IGFBP-1 mRNA levels and decreased not reach statistical significance (P<0.10, Figure 4 ). IGFBP-4 and IGF-I mRNA levels.
Levels of IGF-I mRNA were significantly higher in Overall, IGFBP-1 mRNA levels were increased by aminoguanidine-treated than untreated diabetic rats 212% in untreated diabetic rats (P<0.01, Figure 1a . IGF-I mRNA and peptide levels were therefore IGFBP-1 mRNA levels were significantly increased by coordinate. 206 and 219% in the inner stripe of the outer medulla and cortex of untreated diabetic rats respectively, whereas levels in aminoguanidine-treated diabetic rats Aminoguanidine has no effect on other IGFBPs were not significantly higher than in their non-diabetic IGFBP-5 mRNA was predominantly expressed in the controls ( Figure 1a,c and d) .
inner medulla and inner stripe of the outer medulla Immunohistochemical analysis showed that with lower levels of expression in the cortex (results IGFBP-1 protein was most prominent in collecting not shown). Expression of IGFBP-5 mRNA was 25% ducts ( Figure 2a) . IGFBP-1 was also found in distal lower in diabetic than control rats (diabetes 4069±259 tubules and thick ascending limbs of the cortex vs control 5459±578 arbitrary units, P<0.01) and and outer medulla. IGFBP-1 levels were markedly aminoguanidine treatment had no effect on levels in increased in all of these sites in diabetic rats diabetic or control animals. Diabetes and aminoguani- (Figure 2b) . Aminoguanidine attenuated the diabetes-dine treatment had no effect on expression of mRNA related increase in IGFBP-1 levels (Figure 2c ). for IGFBPs-2, -3 and -6 (results not shown). Changes in IGFBP-1 mRNA and protein levels were therefore coordinate.
Steady-state cortical IGFBP-4 mRNA levels were Discussion decreased by 64% in untreated diabetic rats compared with untreated controls (P<0.001, Figure 3 ). Although levels of IGFBP-4 mRNA were decreased by 36% in Dysregulation of the IGF system has been implicated in the development of experimental diabetic nephroaminoguanidine-treated diabetic rats compared with aminoguanidine-treated controls, this difference was pathy [6 ] . Renal IGF-I levels are transiently elevated in the first 24-72 h after induction of STZ-diabetes not statistically significant (P<0.10, Figure 3) . Levels of IGFBP-4 mRNA were significantly higher in amino-and a role for increased IGF-I activity has been postulated in the development of early diabetes-related guanidine-treated than untreated diabetic rats (P<0.001, Figure 3) . Cortical IGFBP-4 mRNA pre-kidney growth [8, 9] . Long-term studies of diabetic growth hormone/IGF-I-deficient diabetic rats [13] and dominantly reflects proximal tubular expression as confirmed by light microscopic examination of emul-octreotide-treated rats [11] , both of which have decreased urinary albumin excretion and glomerular sion-dipped slides (results not shown).
In vehicle-treated diabetic rats, levels of IGF-I volume, also suggest a role for the IGF system in the longer-term development of structural and functional mRNA in the inner stripe of the outer medulla, representing expression in thick ascending loops of Henle changes of diabetic nephropathy.
In the present study, long-term STZ-diabetes resulted in changes in renal gene expression of a number of components of the IGF system. Firstly, levels of IGF-I mRNA were decreased. Although some [23, 24] , but not other [25] , authors have found transient increases in renal IGF-I mRNA levels soon after the induction of STZ-diabetes, the observations of the present study are consistent with studies demonstrating decreased IGF-I mRNA levels in kidneys from longterm diabetic rats [15, 19, 26 ] . Second, expression of IGFBPs, which are important regulators of IGF actions [14] , is altered early in STZ-diabetic kidneys with many changes persisting for up to 6 months, the longest duration previously studied [19, 20] . Cortical IGFBP-1 mRNA levels were increased in STZ-diabetic kidneys in the present study, consistent with previous observations [16, 19, 20, 27] . IGFBP-1 mRNA levels in the inner stripe of the outer medulla were also increased in diabetic rats in the present study as was observed in our previous study of short-term diabetic rats [20] . These findings contrast with the markedly decreased levels of medullary IGFBP-1 mRNA observed by Landau et al. in both short-and long-term diabetic rats [19] . These inconsistencies may relate to differences in rat strains or severity of diabetes.
The changes in IGF-I and IGFBP-1 mRNA levels were reflected at the protein level in the present study. Localization of proteins was more widespread than that of the mRNA, which is consistent with previous studies [28, 29] . IGF-I and IGFBP-1 found at sites other than those of mRNA expression may reflect paracrine transport of proteins synthesized in the kidney or proteins sourced from the circulation.
Cortical IGFBP-4 levels were decreased in diabetic rat kidney, which is also consistent with previous studies [19, 20, 27] . Unfortunately, attempts to perform IGFBP-4 immunohistochemistry with two different antisera were unsuccessful in the present study. A small decrease in IGFBP-5 mRNA was also observed in diabetic kidneys that is similar in magnitude to the decrease in cortical IGFBP-5 mRNA levels previously reported [19] . In that study, medullary IGFBP-5 levels were unchanged after 180 days of diabetes. Whereas aminoguanidine attenuated diabetes-related changes in expression of IGF-I, IGFBP-1, and IGFBP-4, expression of IGFBP-5 mRNA was not influenced. This suggests that components of the renal IGF system may respond differently to diabetes-induced AGE accumulation.
The diabetic rats in the present study were not treated with insulin and had body weights~30% lower than control rats. Although it is possible that haemo- to haemodynamic and metabolic changes. Aminoguanidine is an inhibitor of AGE formation. IGF actions under different conditions [14] , their role in the development of diabetic kidney disease has not Aminoguanidine treatment substantially retards the development of albuminuria [3, [30] [31] [32] [33] and prevents been completely defined. However, IGFBP-4 is thought to be a purely inhibitory IGFBP [14] , so that relatively mesangial expansion [3, 31, 33] in diabetic rats. Some [33, 34] but not all [3, 31] studies have shown that increased levels of this IGFBP are likely to inhibit IGF actions in the kidney. Aminoguanidine abrogated the aminoguanidine also inhibits glomerular basement membrane thickening induced by diabetes. In the pre-diabetes-induced increase in IGFBP-1 mRNA and protein levels. Cell-associated IGFBP-1, which may be sent study, aminoguanidine treatment significantly blunted the diabetes-related reduction in IGFBP-4 present on proximal tubular cells of diabetic rat kidneys [16 ] , has been implicated in potentiation of IGF mRNA levels. Since IGFBPs may inhibit or potentiate actions [35] . Inhibition of the elevation of levels in this IGFBP by aminoguanidine may therefore also act been increasing interest in the role of the tubulointerstitium in diabetic nephropathy, with declining renal to inhibit renal IGF actions.
The present study did not address the mechanism function more closely correlated to tubulointerstitial rather than glomerular changes [39, 40] . Renal tubules by which aminoguanidine affected the IGF system. It is unlikely that AGEs play a role in the changes in the are a major site of AGE accumulation and many of the receptors involved in mediating AGE-induced IGF system that occur soon after the induction of STZ-diabetes, since they would not have had time to tissue injury or in the clearance of AGEs are located in tubules [41, 42] . Renoprotective therapies have been accumulate. AGE formation may lead to the persistence of abnormal expression of IGF system compon-shown to ameliorate tubular as well as glomerular injury in experimental and human diabetic nephroents by signalling via specific AGE receptors [36 ] . Aminoguanidine treatment would inhibit formation of pathy [43, 44] .
AGEs have been shown to increase IGF-I expression AGE ligands and thereby result in 'normalization' of IGF system expression following the initial perturba-in monocytes [36 ] and glomerular mesangial cells [4] via a receptor-specific mechanism. It may appear that tion due to induction of diabetes. An alternative, indirect mechanism for the effect of aminoguanidine is these findings contradict the present observations that an inhibitor of AGE formation ameliorates the that AGEs regulate synthesis of extracellular matrix components [37] , which in turn may regulate expres-decrease in renal IGF-I levels in diabetic rats. However, these in-vitro experiments do not take the in-vivo milieu, sion of IGFBPs [38] .
Many of the changes in the renal IGF system were whereby renal IGF-I mRNA expression is decreased in long-term diabetic rats, into account. most readily detected in tubules. Indeed, there has 17. Ooi GT, Tseng LY-H, Tran MQ, Rechler MM. Insulin rapidly
In conclusion, long-term treatment of diabetic rats decreases IGFBP-1 gene transcription in streptozotocin-diabetic with aminoguanidine, which has been previously rats. Mol Endocrinol 1992; 6: 2219-2228 shown to inhibit the development of structural and 18. Flyvbjerg 
